Mutant KRAS enhances tumor cell fitness by upregulating stress granules.

Grabocka E., Bar-Sagi D. Cell. 2016 Dec 15;167(7):1803-1813.e12. doi: 10.1016/j.cell.2016.11.035.PMID:27984728

Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein.

Kamphorst JJ, Nofal M, Commisso C, Hackett SR, Lu W, Grabocka E, Vander Heiden MG, Miller G, Drebin JA, Bar-Sagi D, Thompson CB, Rabinowitz JD.

Cancer Res. 2015 Feb 1;75(3):544-53. doi: 10.1158/0008-5472.CAN-14-2211.

Molecular pathways: targeting the dependence of mutant RAS cancers on the DNA damage response.

Grabocka E*, Commisso C, Bar-Sagi D.

Clin Cancer Res. 2015 Mar 15;21(6):1243-7. doi: 10.1158/1078-0432.CCR-14-0650. Epub 2014 Nov 25. Review.*Corresponding Author

Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response.

Grabocka E, Pylayeva-Gupta Y, Jones MJ, Lubkov V, Yemanaberhan E, Taylor L, Jeng HH, Bar-Sagi D.

Cancer Cell. 2014 Feb 10;25(2):243-56. doi: 10.1016/j.ccr.2014.01.005.

Leukemia-associated RhoGEF (LARG) is a novel RhoGEF in cytokinesis and required for the proper completion of abscission.

Martz MK, Grabocka E, Beeharry N, Yen TJ, Wedegaertner PB.

Mol Biol Cell. 2013 Sep;24(18):2785-94. doi: 10.1091/mbc.E12-07-0533. Epub 2013 Jul 24.

Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells.

Commisso C, Davidson SM, Soydaner-Azeloglu RG, Parker SJ, Kamphorst JJ, Hackett S, Grabocka E, Nofal M, Drebin JA, Thompson CB, Rabinowitz JD, Metallo CM, Vander Heiden MG, Bar-Sagi D.

Nature. 2013 May 30;497(7451):633-7. doi: 10.1038/nature12138. Epub 2013 May 12.

RAS oncogenes: weaving a tumorigenic web.

Pylayeva-Gupta Y*, Grabocka E*, Bar-Sagi D.

Nat Rev Cancer. 2011 Oct 13;11(11):761-74. doi: 10.1038/nrc3106. Review.*Equal contribution

Raf-1 and squamous cell carcinoma: Rok-ing the boat.

Grabocka E, Bar-Sagi D.

Cancer Cell. 2009 Aug 4;16(2):85-6. doi: 10.1016/j.ccr.2009.07.012.

Disruption of oligomerization induces nucleocytoplasmic shuttling of leukemia-associated rho Guanine-nucleotide exchange factor.

Grabocka E, Wedegaertner PB.

Mol Pharmacol. 2007 Oct;72(4):993-1002. Epub 2007 Jul 3.

Functional consequences of G alpha 13 mutations that disrupt interaction with p115RhoGEF.

Grabocka E, Wedegaertner PB.

Oncogene. 2005 Mar 24;24(13):2155-65.

Selected Publications
Research Highlights

'Stress coping mechanisms help mutant KRAS cancer cells resist chemo' by Megan Brooks, Reuters Health, December 21, 2016.

'Coping mechanisms suggest new way to make cancer cells more vulnerable to chemotherapy' by Gregory Williams, NYU Medical Center Press Release, December 2016

'Weakness exposed in most common cancer gene' by David March, NYU Medical Center Press Release”, February, 2014.

http://communications.med.nyu.edu/media-relations/news/weakness-exposedmost-common-cancer-gene

'Targeting 'undruggable' cancer mechanism can make chemo more effective' by Emily Mullin, Fierce Biotech Research, February, 2014.

http://www.fiercebiotechresearch.com/story/targeting-undruggable-cancermechanism-can-make-chemo-more-effective-study/2014-02-11

 

'Making K-Ras cancers druggable', Hematology Times. February, 2014.

http://www.hematologytimes.com/p_article.do?id=3916

Media Coverage

'Coping with stress' by Sarah Seton-Rogers. Research Highlight, Nature Reviews Cancer, January 27, 2017

'Mutant RAS calms stressed-out cancer cells' by Kirsten Bryant and Channing Der. Developmental Cell, January 23,2017

'Wild type Ras: Keeping mutant RAS in CHK' by Theonie Anastassiadis and Eric Brown, Preview, Cancer Cell, February 10, 2014.

'HRas and NRas regulate the DNA damage response in KRas-mutant tumors', Cancer Discovery, April, 2014.

'Blind spot found in deadly K-Ras tumors' by Philippa Bourke, Chrysalis, February, 2014.

Grabocka Lab